US Patent

US8481598 — Stable dosage forms of levomilnacipran

Method of Use · Assigned to Individual · Expires 2031-03-02 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects stable dosage forms of levomilnacipran and methods of using these dosage forms.

USPTO Abstract

The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.

Drugs covered by this patent

levomilnacipran-hydrochloride (LEVOMILNACIPRAN HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-839`	—	levomilnacipran-hydrochloride
`U-839`	—	levomilnacipran-hydrochloride
`U-839`	—	levomilnacipran-hydrochloride
`U-839`	—	levomilnacipran-hydrochloride

Patent Metadata

Patent number: US8481598
Jurisdiction: US
Classification: Method of Use
Expires: 2031-03-02
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.